UKHSA Diagnostic and Research Framework (DRF)
Estimated value
£6.3bn
Awarded value
—
Suppliers
0
Lots
2
Published
12 Mar 2026
Description
The UKHSA Diagnostics and Research Open Framework is the successor to the current UKHSA National Microbiology Framework, and predecessor PHE Public Health Microbiology Framework and will be used to support the UK Health Security Agency’s Diagnostics and Research activities for both day to day and incident response. (Please note that it is the potential surge capacity that accounts for the high maximum value of this framework, not anticipated spend) The framework is divided into two lots: Lot One: Diagnostics Goods and Services (products that are UKCA/CE marked or otherwise validated to the required specification), and Lot Two: Research and development (research products that are not UKCA/CE marked) The maximum value (ex VAT) of the framework is set at £6.25 billion The value of Lot 1 is estimated as £5.2b and the value of Lot 2 is estimated as £1.05b. The actual values will vary based on the level of purchasing necessary to provide suitable solutions to the UK’s health protection needs. The maximum value is based on the potential total amount payable exclusive of VAT as estimated by UKHSA, including any potential extension options for call-off contracts. This figure allows for the possibility that a health emergency may occur, such as a pandemic; therefore, the total value of cumulative call-off contracts may be less depending on the potential materialisation of health threats. The value and explanation of how it has been estimated is given in good faith as a guide. It should not be interpreted as an undertaking to purchase any goods or services to any value and does not form part of the Contract.
Scope
- Reference
- C426524
- Total value
- £6,250,000,000 excluding VAT£7,500,000,000 including VATAbove the relevant threshold
- Commercial tool
- Standalone contract
- Contract dates
- 23 Jul 2026 to 23 Jul 2028Possible extension to 23 Jul 2029
each framework in the scheme is expected to run for two years with the option to extend by one year. The end date of any extension is not expected to run past the 8-year mkaximum term
- Main category
- goods
- CPV classifications
- 33124000331000003360000038430000384310003843310038434000384345003843451038434520384345403843455038434570384345803843610038950000504000008514800050410000504110007190000050412000504130005043000050433000731110008511180085145000
- Contract locations
- UK, United Kingdom
- Particular suitability
- Small and medium-sized enterprises (SME)Voluntary, community and social enterprises (VCSE)
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Meet minimum requirements for whichever lot(s) you are applying for - see ITT | — | quality | — |
Participation
Conditions suppliers must meet to bid.
Conditions of participation are fully detailed within the procurement documents accessible via the Authority's e-procurement portal Atamis
Must be able to provide t least one appropriately certified, accredited or licenced products or services described in the Lot Specific Requirements which are fully detailed within the procurement documents accessible via the Authority's e-procurement portal Atamis
Submission & procedure
- Enquiry deadline
- 24 Mar 2026, 10:00 am
- Submission deadline
- 08 Apr 2026, 9:00 am
- Submission address
- Application is via submission of a tender response by the deadline stated above via the Health Family’s e-Sourcing Portal, Atamis, Ref C426524 UKHSA Diagnostics and Research Open Framework. https://atamis-1928.my.site.com/s/Welcome
- Electronic submission
- Yes
- Procedure
- Open procedure
Lots · 2 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | In-vitro diagnostic medical devices and associated services | £5.2bn | active |
| 2 | Goods and services mainly for research & development, experimentation & study | £1.1bn | active |